
Bio-Techne Reports Stable Fiscal Year Revenue Amid Pending Acquisition
Bio-Techne Corporation reported flat full-year revenue of $1.2 billion for fiscal 2026, even as it prepares for an $11.3 billion acquisition by Merck KGaA. The Minneapolis-based life sciences firm saw fourth-quarter organic revenue rise 3%, signaling steady demand for its research reagents and diagnostic platforms during the transition period.


























